EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cost-Effectiveness of Pembrolizumab Monotherapy for High Programmed Death Ligand 1 Advanced or Metastatic Non-small Cell Lung Cancer Depends on Long-Term Survivors

Zakile A Mfumbilwa, Janneke A Wilschut, Harry J M Groen, Valesca P Retèl, Bram Ramaekers, Manuela Joore, Veerle M H Coupé

Clinical Drug Investigation · 2025

DOI: 10.1007/s40261-025-01456-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Drug Investigation, 2025. Verfasst von Zakile A Mfumbilwa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Data Science, Disease Modelling and Health Care Evaluation, Amsterdam UMC, location Vrije Universiteit Amsterdam, De B…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, B7-H1 Antigen. Die Arbeit nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pembrolizumab shows effectiveness in treating metastatic non-small cell lung cancer (metNSCLC), with a subgroup of patients experiencing long-term survival (LTS) benefits. The existence of a LTS subgroup may influence the cost-effectiveness of pembrolizumab monotherapy compared with platinum-based chemotherapy. This study aims to assess the potential implications of such a subgroup on the cost-effectiveness for patients with non-squamous metNSCLC and PD-L1 ≥ 50% who are ineligible for targeted therapies. METHODS: This study used a decision analytic model based on Dutch real-world data (2008-2014). Two strategies were simulated: (1) a chemotherapy strategy: patients receive chemotherapy in the first-, second-, and third-line; and (2) a pembrolizumab strategy: patients receive first-line pembrolizumab followed by chemotherapy for those progressing to second- and third-lines. The pembrolizumab strategy is evaluated with and without the assumption that there is a LTS subgroup. The LTS subgroup is assumed to be free from metNSCLC-related progression after treatment. Costs (2022 €), including drug costs, other direct medical costs, family costs, and healthcare costs in life years gained, are considered from first-line treatment to death. Effects are measured in quality-adjusted life years (QALYs). The incremental cost-effectiveness ratio (ICER) is assessed using an €80,000/QALY threshold. Threshold analyses are performed on the size and mortality rate of the LTS subgroup and on the price of pembrolizumab. RESULTS: QALYs per patient were 0.65 for chemotherapy, 1.24 for pembrolizumab without LTS, and 3.52 for pembrolizumab with LTS. Average costs per patient were €58,800 for chemotherapy, €154,600 for pembrolizumab without LTS, and €178,600 for pembrolizumab with LTS. Pembrolizumab without LTS was not cost-effective compared with chemotherapy (ICER €167,600/QALY), but pembrolizumab with LTS (30% of simulated population) was cost effective (ICER of €43,100/QALY). Threshold analyses showed that a LTS subgroup size of at least 10% or halving the price of pembrolizumab was needed for pembrolizumab to be cost-effective. CONCLUSIONS: Pembrolizumab is a cost-effective first-line treatment for patients with metNSCLC and PD-L1 ≥ 50% in the Netherlands when at least 10% of patients are long-term survivors. Without long-term survivors, this treatment is not cost-effective. Therefore, it is crucial to consider long-term survivors in assessing the cost-effectiveness of immunotherapy in metNSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCarcinoma, Non-Small-Cell LungLung NeoplasmsB7-H1 AntigenAntineoplastic Agents, ImmunologicalHumansCost-Benefit AnalysisQuality-Adjusted Life YearsMaleNetherlandsFemale

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedB7-H1 AntigenAntineoplastic Agents, ImmunologicalCD274 protein, human

Autor:innen und Institutionen

  • Department of Epidemiology and Data Science, Disease Modelling and Health Care Evaluation, Amsterdam UMC, location Vrije Universiteit Amsterdam, De Boelelaan 1117, PO Box 7057, 1007 MB, Amsterdam, The Netherlands.
  • Amsterdam Public Health, Methodology, Amsterdam, The Netherlands.
  • Department of Mathematics and Statistics, Sokoine University of Agriculture, Morogoro, Tanzania.
  • Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Department of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.

Förderung

  • ZonMw

Zitieren

APA

Mfumbilwa, Z. A., Wilschut, J. A., Groen, H. J. M., Retèl, V. P., Ramaekers, B., Joore, M., & Coupé, V. M. H. (2025). Cost-Effectiveness of Pembrolizumab Monotherapy for High Programmed Death Ligand 1 Advanced or Metastatic Non-small Cell Lung Cancer Depends on Long-Term Survivors. Clinical Drug Investigation. https://doi.org/10.1007/s40261-025-01456-5

Vancouver

Mfumbilwa ZA, Wilschut JA, Groen HJM, Retèl VP, Ramaekers B, Joore M, et al. Cost-Effectiveness of Pembrolizumab Monotherapy for High Programmed Death Ligand 1 Advanced or Metastatic Non-small Cell Lung Cancer Depends on Long-Term Survivors. Clinical Drug Investigation. 2025. doi:10.1007/s40261-025-01456-5

BibTeX
@article{Mfumbilwa2025,
  author = {Mfumbilwa, Zakile A and Wilschut, Janneke A and Groen, Harry J M and Retèl, Valesca P and Ramaekers, Bram and Joore, Manuela and Coupé, Veerle M H},
  title = {Cost-Effectiveness of Pembrolizumab Monotherapy for High Programmed Death Ligand 1 Advanced or Metastatic Non-small Cell Lung Cancer Depends on Long-Term Survivors},
  journal = {Clinical Drug Investigation},
  year = {2025},
  doi = {10.1007/s40261-025-01456-5}
}
Kostenlos starten →